- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03820050
FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study
June 14, 2019 updated by: Abbott Diabetes Care
The purpose of this study is to characterize the Freestyle Libre Flash Glucose Monitoring System in pediatric subjects with respect to YSI reference venous plasma sample measurements.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Up to 250 subjects will be enrolled at up to six (6) clinical research sites in the United States.
Subjects will wear two Sensors.
Each Sensor will have a paired Reader that will be given to the subject.
All Readers will be masked during the study (i.e.
subjects will not be able to view glucose results obtained from the Sensor on the Reader screen).
Subjects will be asked to perform at least 4 capillary Blood Glucose (BG) tests per day using the primary Reader.
Interstitial glucose readings from each Sensor will be obtained with the corresponding Readers immediately following each BG test.
Subjects will be instructed to report any problems with the device.
Subjects will make three (3), four (4) or five (5) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1).
Based on the subjects weight, subjects will have up to two (2) in-clinic visits during which intravenous blood draws and YSI reference testing will occur.
Study Type
Observational
Enrollment (Actual)
144
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93105
- Sansum Diabetes Research Institute
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Barbara Davis Center for Diabetes
-
-
Idaho
-
Idaho Falls, Idaho, United States, 94502
- Rocky Mountain Diabetes and Osteoporosis Center
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Diabetes and Glandular Disease Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 17 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Pediatric subjects aged 4-17 with Type 1 or Type 2 diabetes.
Description
Inclusion Criteria:
- Subject must be between the ages of 4 and 17 years of age at the time of study enrollment.
- Subject must have type 1 or type 2 diabetes.
- Subjects age 11 and older must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
- Willing to perform a minimum of 4 finger sticks per day while wearing the sensor in the study.
- Subject and/or guardian must be able to read and understand English.
- For subjects age 6 and older: willing to allow medical personnel to insert an IV catheter in the arm to allow for venous blood flow samples to be obtained per the study protocol.
- For subjects age 11 and older: subject is willing to have their blood sugar manipulated during one or more in-clinic sessions.
- In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
- At the time of enrollment, subject must be available to participate in all study visits.
- Known insulin sensitivity factor (only applicable to subjects age 11 and older).
- Subject's parent, guardian or legally authorized representative must be willing and able to provide written informed consent.
- Subject must be willing and able to provide written signed and dated informed assent when appropriate.
Exclusion Criteria:
- Subject is 18 years of age or older.
- Subject has a history of hypoglycemia unawareness (only applicable to subjects age 11 and older).
- Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
- Subject is known to be pregnant or becomes pregnant during the study (applicable to female subjects only).
- Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
- Subject has had an episode of severe hypoglycemia requiring intervention from a health care professional(i.e. EMT assistance, emergency room visit, or hospital admission) within the last six (6) months (only applicable to subjects age 11 or older).
- Subject has had an episode of diabetic ketoacidosis (DKA) within the last (3) months (only applicable to subjects age 11 or older).
- Subject is currently participating in another clinical trial.
- Subject has donated blood within 112 days (3.7 months) prior to the beginning of the study activities (only applicable to subjects age 6 and older).
- Subject has both hemoglobin (Hb) and hematocrit levels that are below the normal ranges (only applicable to subjects age 6 and older). The low end of the normal range for Hb is as follows: for males and females aged 6-12 years old it is 11.5 g/dL; for males aged 12-17 it is 13.0 g/dL; for females aged 12-17 it is 12.0 g/dL. The low end of the normal hematocrit for males and females aged 6-12 is 35%; 37% for males aged 12-17 and 36% for females aged 12- 17).
- Subject has X-ray, MRI, CT or diathermy appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
- Subject is unsuitable for participation due to any other cause as determined by the Investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
System Performance
Time Frame: 45 days
|
System Performance will be characterized with respect to YSI reference venous plasma measurements
|
45 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Shridhara Karinka, Ph.D., Abbott Diabetes Care
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 29, 2019
Primary Completion (ACTUAL)
June 14, 2019
Study Completion (ACTUAL)
June 14, 2019
Study Registration Dates
First Submitted
January 25, 2019
First Submitted That Met QC Criteria
January 25, 2019
First Posted (ACTUAL)
January 29, 2019
Study Record Updates
Last Update Posted (ACTUAL)
June 18, 2019
Last Update Submitted That Met QC Criteria
June 14, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- ADC-US-VAL-18175
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Freestyle LIbre Flash Glucose Monitoring System
-
Abbott Diabetes CareCompleted
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownDiabetes Mellitus, Type 2 | Flash Glucose MonitoringChina
-
Abbott Diabetes CareCompleted
-
Jessa HospitalUnknownMetabolic Control | Flash Glucose MonitoringBelgium
-
Abbott Diabetes CareCompleted
-
Abbott Diabetes CareCompleted
-
Abbott Diabetes CareCompleted
-
Abbott Diabetes CareCompletedDiabetes MellitusUnited Kingdom, Germany, Ireland
-
Abbott Diabetes CareTerminatedDiabetes MellitusUnited States
-
Abbott Diabetes CareCompletedDiabete MellitusUnited States